| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 2 Mar 2026 | 2 Mar 2026 |
| Board meeting for approval of basis of allotment for right issue | ||
| Board Meeting | 16 Feb 2026 | 16 Feb 2026 |
| This is in reference to the Outcome of the Meeting of Board of Directors dated January 20, 2026, we wish to inform you that the Board of Directors of Dr Lalchandani Labs Limited, at its meeting held on today i.e. February 16, 2026, has considered and approved the extension of the closing date of the ongoing rights issue. The Rights Issue, which opened on Wednesday, February 04, 2026, and originally scheduled to close on Friday, February 20, 2026, has now been extended until Friday, February 27, 2026. The extension has been granted to facilitate better participation from eligible shareholders and to provide them with adequate time to subscribe to the Rights Issue. | ||
| Board Meeting | 20 Jan 2026 | 16 Dec 2025 |
| Dr Lalchandani Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/12/2025 inter alia to consider and approve fixation of the record date; ? determination of the issue price; ? determination of the rights entitlement ratio; and ? such other terms and conditions as may be required in accordance with applicable laws subject to receipt of necessary statutory and regulatory approvals. This is with reference to our prior intimation dated December 16, 2025, wherein we had informed the Exchange about the meeting of the Board of Directors of Dr Lalchandani Labs Limited (the Company) scheduled to be held on Monday, December 22, 2025, inter alia, to consider and approve matters relating to the proposed Rights Issue, including fixation of the record date, issue price, entitlement ratio and other related terms. We wish to inform you that the aforesaid Board Meeting scheduled to be held on December 22, 2025 has been deferred due to the non-receipt of In-Principle Approval from BSE Limited for the proposed Rights Issue. (As Per BSE Announcement Dated on:22.12.2025) In continuation of our earlier intimation dated December 16, 2025, and subsequent deferment notice dated December 22, 2025, we wish to inform you that the meeting of the Board of Directors of Dr Lalchandani Labs Limited (the Company) was duly held today, i.e., Tuesday, January 20, 2025, to consider and approve matters relating to the proposed Rights Issue of Equity Shares of the Company. Revised Outcome Of The Board Meeting Held On January 20, 2026 For Approving Terms Of Rights Issue (As per BSE Announcement dated on: 20.01.2026) | ||
| Board Meeting | 15 Dec 2025 | 2 Dec 2025 |
| Dr Lalchandani Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/12/2025 ,inter alia, to consider and approve raising of funds through a rights issue and/or any other permissible mode. Outcome of Board Meeting (As Per BSE Announcement Dated on: 09/12/2025) Raising of funds through the issuance of equity shares of face value ?10 each by way of rights issue for an amount not exceeding Rs 433.31 Lakhs, to the eligible equity shareholders of the Company as on the record date (to be determined and notified subsequently), subject to receipt of statutory / regulatory approvals in accordance with the amended SEBI (Issuer of Capital and Disclosure Requirements) Amendment Regulations, 2025 (the SEBI ICDR Regulations) and other applicable regulations and subject to necessary approvals as may be required. (As per BSE Announcement dated on: 15.12.2025) | ||
| Board Meeting | 14 Nov 2025 | 10 Nov 2025 |
| Dr Lalchandani Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 inter alia to consider and approve Financial Statements for the half year ended 30.09.2025 Unaudited Financial results September 30, 2025 Unaudited Financial Results for the half year ended September 2025 (As Per BSE Announcement Dated on 14.11.2025) | ||
| Board Meeting | 5 Sep 2025 | 5 Sep 2025 |
| Outcome of Board Meeting held on today i.e. September 05, 2025 | ||
| Board Meeting | 1 May 2025 | 25 Apr 2025 |
| Dr Lalchandani Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/05/2025 inter alia to consider and approve the Audited Financial Statements of the Company for the Financial Year ending on March 2025 Audited Financial results for Year ended March 31, 2025 (As Per BSE Announcement Dated on 01.05.2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
